Tejas Savant
Stock Analyst at Morgan Stanley
(2.37)
# 2,525
Out of 5,157 analysts
256
Total ratings
42.36%
Success rate
-0.73%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $32.78 | +12.87% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $15.07 | +26.08% | 4 | Mar 6, 2026 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $10 | $8.31 | +20.34% | 15 | Mar 5, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $50.90 | +37.52% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $198.95 | +25.66% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $48.67 | +23.28% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $500.08 | +33.98% | 16 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $170.93 | +55.03% | 12 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $20.46 | -2.25% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $75.54 | +0.61% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $14.52 | +10.19% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $122.35 | -14.18% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $8.15 | +47.24% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $8.56 | -6.54% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.23 | +65.48% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $7.88 | -11.17% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.50 | +42.86% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $5.12 | +310.16% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.37 | +45.99% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $6.34 | +530.91% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.43 | +146.91% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.49 | +122.72% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $4.13 | -33.41% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.77 | +464.97% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $90.49 | -19.33% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $167.37 | +49.37% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $18.72 | +434.19% | 5 | May 12, 2022 |
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $32.78
Upside: +12.87%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $15.07
Upside: +26.08%
Personalis
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $8.31
Upside: +20.34%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $50.90
Upside: +37.52%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $198.95
Upside: +25.66%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $48.67
Upside: +23.28%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $500.08
Upside: +33.98%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $170.93
Upside: +55.03%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $20.46
Upside: -2.25%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $75.54
Upside: +0.61%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $14.52
Upside: +10.19%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $122.35
Upside: -14.18%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $8.15
Upside: +47.24%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $8.56
Upside: -6.54%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.23
Upside: +65.48%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $7.88
Upside: -11.17%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.50
Upside: +42.86%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $5.12
Upside: +310.16%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.37
Upside: +45.99%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $6.34
Upside: +530.91%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.43
Upside: +146.91%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.49
Upside: +122.72%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $4.13
Upside: -33.41%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.77
Upside: +464.97%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $90.49
Upside: -19.33%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $167.37
Upside: +49.37%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $18.72
Upside: +434.19%